CXCR3 Expression Is Associated with Advanced Tumor Stage and Grade Influencing Survival after Surgery of Localised Renal Cell Carcinoma.

ABSTRACT:

Background

Surgery is the standard treatment in localized renal cell carcinoma (RCC). Pembrolizumab is now approved for adjuvant therapy in high-risk patients. However, inhomogeneity of studies gives ambiguity which patient benefit most from adjuvant therapy. A high infiltration of CD8⁺ T cells is known to be linked with poor prognosis in RCC. CXCR3 is a key player of CD8⁺ T cell differentiation and infiltration. We aimed to evaluate CXCR3 as a potential marker for predicting recurrence.

Methods

CXCR3 and immune cell subsets (CD4, CD8, CD68 and FoXP3) were measured on RCC samples by multiplex immunofluorescence (mIF) staining. Cellular localization of CXCR3 was evaluated using single-cell RNA analysis on a publicly available dataset.

Results

Tumo

SUBMITTER: Lindner AK 

PROVIDER: S-EPMC9954014 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature